Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

Abstract: This invention relates to compounds that are inhibitors of HSP70 protein, and applications thereof.

Abstract: HSP110 is involved in multiple tumorigenic processes but no inhibitor was known to date. The inventors have identified for the first time HSP110 inhibitors. These inhibitors bind directly to the nucleotide binding domain of HSP110 and then blocks the phosphorylation of STAT3, cancer cell growth or MyD88 stability. The present invention relates to a compound of general formula (I) for use in the treatment of a HSP 110-associated cancer, for example colorectal cancer and lymphoma. Especially the inventors tested the compound on two different colorectal mice models, a syngeneic model for which mouse colon cancer CT-26 cells were injected into Balb/c mice and a NOD/SCID model in which mice were implanted with human colorectal cancer HCT116 cells. In those animals bearing a tumor, the compound induced tumor regression that was associated with the inhibition of other HSP110 reported tumorigenic functions (resistance to apoptosis, induction of pro-tumor macrophages).

Abstract: The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.

Abstract: The present invention relates to lipoproteins containing platinum complex. The invention also relates to a kit comprising said lipoproteins. In particular, the present invention relates to the use of said platinum-complex-bearing lipoproteins for the specific targeting of macrophages and tumour cells in the treatment of cancer.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

Abstract: A method for the expression of a protein of interest by a bacterium, notable in that it comprises the culturing of a bacterium temporarily or continuously expressing an Hsp protein, in that said bacterium also comprises a nucleic acid sequence, encoding a protein of interest, under the control of a lac promoter and in that said bacterium is cultured in a medium which does not contain IPTG or a metabolized molecule in such a way as to automatically induce the induction of transcription from the lac promoter.

Abstract: The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.

Abstract: A method for the expression of a protein of interest by a bacterium, notable in that it comprises the culturing of a bacterium temporarily or continuously expressing an Hsp protein, in that said bacterium also comprises a nucleic acid sequence, encoding a protein of interest, under the control of a lac promoter and in that said bacterium is cultured in a medium which does not contain IPTG or a metabolized molecule in such a way as to automatically induce the induction of transcription from the lac promoter.

Abstract: The invention relates to methods for diagnosing cancer and determining the responsiveness to chemotherapyin a subject based on the detection of HSP70-expressing exosomes in a bodily fluid sample obtained from said subject. The invention also relates to methods for treating cancer and in particular methods for restoring or enhancing the anti-tumor immune response in a patient in need thereof by inhibiting the activation MDSC as well as methods for inhibiting or reducing HSP70-expressing exosomes-mediated tumor resistance against a chemotherapeutic agent and therefore methods for restoring or enhancing the efficacy of said chemotherapeutic agent.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.